Pituitary Adenylate Cyclase-Activating
Polypeptide-38

The Discovery

Act One: The Mystery Signal

In 1989, a team of Japanese scientists led by Dr.

In 1989, a team of Japanese scientists led by Dr. Akira Miyata was studying the hypothalamus — the brain's master control center for hormones. They were searching for new molecules that could stimulate a chemical called cyclic AMP, which helps cells communicate. Using tissue from sheep brains, they discovered a completely unknown peptide that was extraordinarily powerful at activating this signaling pathway. It was 38 amino acids long, and they named it PACAP-38: Pituitary Adenylate Cyclase-Activating Polypeptide. The name was a mouthful, but the discovery was elegant. They had found one of the brain's most important signaling molecules hiding in plain sight.

The Breakthrough

Act Two: Naming the Mystery

After the discovery, scientists around the world began mapping where PACAP-38 existed in the body.

After the discovery, scientists around the world began mapping where PACAP-38 existed in the body. They found it everywhere: the brain, the spinal cord, the gut, the immune system, the adrenal glands. It wasn't just a brain hormone — it was a universal messenger. PACAP-38 belonged to a family of peptides that included VIP (vasoactive intestinal peptide), but it was far more potent. Researchers identified two forms: PACAP-38 (the full-length version) and PACAP-27 (a shorter version). PACAP-38 was the dominant form in the brain, suggesting it played a critical role in neural function.

The Trials

Act Three: The Bodyguard Discovery

Through the 1990s and 2000s, researchers made a remarkable finding: PACAP-38 protected brain cell...

Through the 1990s and 2000s, researchers made a remarkable finding: PACAP-38 protected brain cells from dying. In animal models of stroke, Alzheimer's disease, Parkinson's disease, and traumatic brain injury, PACAP-38 reduced brain damage significantly. It worked by activating survival pathways inside neurons, telling them to resist damage rather than self-destruct. Scientists called it a neuroprotective peptide. In experiments, rats given PACAP-38 after a stroke had 50-60% less brain damage than untreated rats. The peptide also reduced inflammation in the brain, which is a major driver of ongoing damage after injury.

The Crisis

Act Four: Migraine Connection

In 2009, researchers made a surprising discovery that changed the direction of PACAP research.

In 2009, researchers made a surprising discovery that changed the direction of PACAP research. They found that injecting PACAP-38 into migraine patients reliably triggered migraine attacks. This meant PACAP-38 was directly involved in causing migraines. Pharmaceutical companies immediately saw an opportunity: if you could block PACAP-38's receptor, you might prevent migraines. Several companies began developing anti-PACAP antibodies and receptor blockers. This approach was similar to the successful CGRP-blocking migraine drugs already on the market, but targeted a different pathway that might help patients who don't respond to CGRP treatments.

The Legacy

Act Five: From Lab to Hospital

Today, PACAP-38 research moves in two opposite directions.

Today, PACAP-38 research moves in two opposite directions. For migraines, scientists are trying to block it. For brain injuries and neurodegenerative diseases, they want to deliver more of it. Several anti-PACAP antibodies are in clinical trials for migraine prevention. Meanwhile, researchers are developing intranasal delivery systems that could spray PACAP-38 directly into the brain through the nose to treat stroke and Alzheimer's disease. The dual nature of PACAP-38 — villain in migraines, hero in brain injuries — makes it one of the most fascinating peptides in neuroscience. The molecule discovered in sheep brains in 1989 may soon become medicine for millions of people.